Nuclear Medicine is a unique specialty of clinical medicine in modern healthcare systems. It aims at providing both diagnostic tools and therapeutic options using slightly radioactive drugs for a wide range of pathologies.
Medical need covering is supported by a broad-spectrum of technologies and innovations based on radiopharmaceuticals (radiolabelled pharmaceuticals products) and medical devices (imaging and software equipment, implantable therapeutic products).
Over the past decade a series of technological innovations in nuclear medicine allowed a predictive and more precise and more personalized patient management. Recent innovations fostered an impressive growth of “theranostic” approaches combining both diagnostic and therapeutic action within the same technology.,
“Innovation” is a Topical Working Group within the AIPES organization with the aim to provide a gateway to detecting and understanding innovation in the field of non-invasive imaging and therapies involving broad-spectrum nuclear medicine technologies. Selected experts of member companies from imaging and pharmaceutical industries set up the Innovation Working Group joining their extensive experience in applied and advanced imaging technology.
The Group receives input from its members on current innovations and associated developments worldwide., Together with the AIPES Executive Committee, WG Innovation highlights promising developments to all AIPES members.
In view of the rapid advances and significant changes in nuclear medicine, the group develops educational activities and provides teaching materials for the AIPES related-communities: patients, medical/nuclear physicians and decision makers/influencers. In close collaboration with the AIPES Executive Committee, the group monitors EU Research initiatives and advises AIPES members on potential support activities of these initiatives.
Furthermore, the group informs the AIPES members on topics of interest from the nuclear medicine community and initiates as well as supports survey activities.
WG Innovation liaises closely with complementary working groups or committees within other European organizations to actively support nuclear medicine innovation, training and development with a particular focus on projects and strategies towards personalized, medicine.
Jean Michel Geets, Chairman IBA Radiopharma Solutions, Belgium
Mart Jan Blauwhoff, Vice Chairman Curium The Netherlands
Antonis Kalemis, President NMEu & Supervisor Siemens Healthineers
Florence Chossat Curium France
Jean-François Gestin Atlanpole Biotherapies, France
Fabrice Giacomelli Nucleis, Belgium
Ira Goldman Lantheus Medical Imaging, Ireland
Angel Hijos Lilly, France
Maria-Jose Martinez Philips, The Netherlands
Jean-Luc Morelle Trasis, Belgium
Stanley Satz AIP- Advance Innovative Partners, Germany
Ayfer Soylou Monrol, Romania
Ewout VanSteenkiste Molecubes, Belgium
Samuel Voccia ANMI Telix, Belgium